Open | $14.000 |
Close | $14.000 |
Volume / Avg. | 640.526K / 626.502K |
Day Range | 13.760 - 14.110 |
52 Wk Range | 7.070 - 15.433 |
Market Cap | $860.967M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 53 |
Short Interest | 8.09% |
Days to Cover | 9.03 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Evolus (NASDAQ: EOLS) through any online brokerage.
Other companies in Evolus’s space includes: GH Research (NASDAQ:GHRS), Verona Pharma (NASDAQ:VRNA), WAVE Life Sciences (NASDAQ:WVE), Tarsus Pharmaceuticals (NASDAQ:TARS) and Phibro Animal Health (NASDAQ:PAHC).
The latest price target for Evolus (NASDAQ: EOLS) was reported by Stifel on Friday, March 8, 2024. The analyst firm set a price target for 25.00 expecting EOLS to rise to within 12 months (a possible 78.57% upside). 15 analyst firms have reported ratings in the last year.
The stock price for Evolus (NASDAQ: EOLS) is $14 last updated March 18, 2024 at 4:00 PM EDT.
There are no upcoming dividends for Evolus.
Evolus’s Q1 earnings are confirmed for Tuesday, May 7, 2024.
There is no upcoming split for Evolus.
Evolus is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.